Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lein

Showing results (31-40 of 101) with videos related to

Pageof 11
Sort By:
Techniques in Urology|April 1, 1996
Laparoscopic adrenalectomyD Fahlenkamp, M Beer, B Schönberger, et al.
International Journal of Cancer|April 22, 1997
Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancerK Jung, L Nowak, M Lein, et al.
Clinical Chemistry|December 1, 1996
Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in bloodK Jung, L Nowak, M Lein, et al.
Clinical Chemistry|October 1, 1995
Rapid screening of PSA: evaluation of an immunochemical membrane strip testM Lein, K Jung, D Schnorr, et al.
International Journal of Cancer|January 8, 1998
Factors influencing the ratio of free to total prostate-specific antigen in serumA Meyer, K Jung, M Lein, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 15, 1996
What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?K Jung, L Nowak, M Lein, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 30, 2000
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancerC Stephan, K Jung, M Lein, et al.
Der Urologe. Ausg. A|September 17, 1998
[Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma]M Lein, L Nowak, K Jung, et al.
The Journal of Urology|December 18, 2001
Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001C Stephan, K Jung, D Schnorr, et al.
Clinical Chemistry and Laboratory Medicine|February 24, 2001
Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditionsK Jung, M Lein, B Brux, et al.
Pageof 11

Showing results (31-40 of 101) with videos related to

Sort By:
Pageof 11
Techniques in Urology|April 1, 1996
Laparoscopic adrenalectomyD Fahlenkamp, M Beer, B Schönberger, et al.
International Journal of Cancer|April 22, 1997
Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancerK Jung, L Nowak, M Lein, et al.
Clinical Chemistry|December 1, 1996
Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in bloodK Jung, L Nowak, M Lein, et al.
Clinical Chemistry|October 1, 1995
Rapid screening of PSA: evaluation of an immunochemical membrane strip testM Lein, K Jung, D Schnorr, et al.
International Journal of Cancer|January 8, 1998
Factors influencing the ratio of free to total prostate-specific antigen in serumA Meyer, K Jung, M Lein, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 15, 1996
What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?K Jung, L Nowak, M Lein, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 30, 2000
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancerC Stephan, K Jung, M Lein, et al.
Der Urologe. Ausg. A|September 17, 1998
[Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma]M Lein, L Nowak, K Jung, et al.
The Journal of Urology|December 18, 2001
Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001C Stephan, K Jung, D Schnorr, et al.
Clinical Chemistry and Laboratory Medicine|February 24, 2001
Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditionsK Jung, M Lein, B Brux, et al.
Pageof 11